InvestmentJul 22, 2026, 04:31 PM
Mentari Therapeutics Secures Additional $200M Private Placement
AI Summary
Mentari Therapeutics, Inc. announced an additional $200 million private placement from new and existing investors. This financing, which is an amendment to a previously reported Securities Purchase Agreement, will extend Mentari's cash runway into 2029 and fund its migraine prevention pipeline, including Phase 2a readouts for its PACAP-targeted lead programs. The private placement is expected to close immediately prior to Mentari's merger with InMed Pharmaceuticals Inc., after which Mentari stockholders will own approximately 98.85% of the combined entity.
Key Highlights
- Mentari Therapeutics secured an additional $200 million private placement from new and original investors.
- The financing extends Mentari's cash runway into 2029 and through Phase 2a readouts for two PACAP-targeted lead programs, including MT-002.
- The private placement supports the clinical development of Mentari’s broader migraine prevention pipeline.
- Mentari stockholders are expected to own approximately 98.85% of the combined company post-merger with InMed Pharmaceuticals.
- InMed Pharmaceuticals shareholders are expected to own approximately 1.15% of the combined company.
- The total shares of the combined company on an as-converted/as-exercised basis are expected to be approximately 601,195,812.
Price Impact
More from INM